Into the future: a single EU body assessing relative effectiveness of medicines?
This article was originally published in SRA
A fully centralized European health technology assessment is probably not a possibility as member states individually are responsible for decisions on access to medicines via their respective national health systems. But what about a central EU expert body responsible for producing a single relative effectiveness assessment that national committees could use in their own HTA and pricing/reimbursement discussions and decisions?
You may also be interested in...
In addition to our daily in-depth coverage of key events relating to the COVID-19 pandemic, we’re bringing you a periodic round-up of other developments. This edition covers Europe and other countries.
The US company is bringing extra supplies of lopinavir/ritonavir into France but stresses that the combination treatment is not authorized for treating patients with the coronavirus.
As part of its efforts to preserve patient access to medicines amid the COVID-19 pandemic, Russia is planning to cap drug prices if increases of more than 30% are detected. It will also allow online sales of non-prescription drugs and may also tighten the rules on fake and substandard products.